Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_12A8F7D8B626
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Périodique
Haematologica
ISSN
1592-8721 (Electronic)
ISSN-L
0390-6078
Statut éditorial
Publié
Date de publication
01/2018
Peer-reviewed
Oui
Volume
103
Numéro
1
Pages
e39-e41
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Mots-clé
Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Biopsy, Combined Modality Therapy, Histiocytic Sarcoma/diagnosis, Histiocytic Sarcoma/drug therapy, Histiocytic Sarcoma/metabolism, Humans, Imatinib Mesylate/administration & dosage, Immunohistochemistry, Immunophenotyping, Male, Molecular Targeted Therapy, Positron Emission Tomography Computed Tomography, Pyridones/administration & dosage, Pyrimidinones/administration & dosage, Retreatment, Symptom Assessment, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/11/2017 8:18
Dernière modification de la notice
21/11/2022 8:11
Données d'usage
